featured
CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection vs Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
J. Clin. Oncol 2018 Jul 19;[EPub Ahead of Print], JE Lancet, GL Uy, JE Cortes, LF Newell, TL Lin, EK Ritchie, RK Stuart, SA Strickland, D Hogge, SR Solomon, RM Stone, DL Bixby, JE Kolitz, GJ Schiller, MJ Wieduwilt, DH Ryan, A Hoering, K Banerjee, M Chiarella, AC Louie, BC MedeirosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.